Applications of Artificial Intelligence in Biotechnology: Current Trends and Future Prospects

Abstract

Artificial intelligence (AI) is becoming an important tool in biotechnology research because it can analyse large and complex biological datasets more quickly than traditional approaches. Applications include drug discovery, genomics, protein-structure prediction, disease diagnosis, personalised medicine, and biomanufacturing. This paper reviews the main uses of AI in biotechnology and examines its possible benefits, including faster research, improved prediction, automation, and reduced development costs. It also discusses limitations such as poor-quality data, algorithmic bias, lack of explainability, privacy risks, and difficulties in validating AI-generated results. The review argues that AI should be treated as a decision-support technology rather than a replacement for biological expertise. Responsible adoption requires high-quality datasets, human oversight, transparent methods, secure data governance, and appropriate regulation. The paper concludes that AI is neither completely good nor completely bad in biotechnology. Its value depends on how it is designed, tested, and used. When combined with laboratory validation and ethical safeguards, AI can strengthen biotechnology research and support the development of safer and more effective solutions.

Introduction

The text examines how Artificial Intelligence (AI) can improve biotechnology research while highlighting the technical, ethical, legal, and social challenges that must be addressed for its responsible use.

• Biotechnology generates large and complex datasets from DNA sequencing, protein analysis, medical imaging, electronic health records, and laboratory experiments. Traditional manual analysis is often slow and difficult, while AI, machine learning, and deep learning can process these datasets efficiently and identify complex patterns.
• AI can support biotechnology by recognising patterns, making predictions, automating analysis, and helping researchers make decisions. However, biological data are highly variable, so AI results must be validated using independent datasets, laboratory experiments, and, where necessary, clinical studies.
• Major applications include:
  • Drug discovery: identifying biological targets, screening molecules, predicting molecular interactions, designing drugs, and repurposing existing drugs.
  • Genomics: analysing DNA and RNA data, classifying genetic variants, and identifying relationships between genes and diseases.
  • Diagnosis and personalised medicine: analysing medical images and patient information to support diagnosis and treatment selection.
  • Biomanufacturing: monitoring production processes and identifying conditions associated with quality problems or failures.
• The major benefits of AI include increased speed, scalability, automation, improved pattern recognition, integration of different types of biological data, and potential reductions in research time and cost.
• Despite these advantages, AI faces important limitations and risks. Poor-quality or incomplete datasets can produce inaccurate results, while biased datasets may disadvantage underrepresented populations. Black-box models may also be difficult to interpret, and genetic and health information requires strong privacy protection.
• AI-generated predictions should not automatically be treated as scientific evidence. Important predictions require experimental confirmation because correlations identified by AI do not necessarily demonstrate biological causation.
• Healthcare applications require particular caution because incorrect AI recommendations can affect patient safety, autonomy, equity, and accountability. AI should therefore support rather than replace qualified professionals.
• The paper identifies a theoretical gap between AI's technical performance and responsible biotechnology practice. A useful AI system should be not only accurate but also reproducible, interpretable, secure, scientifically valid, and appropriate for the population or biological system studied.
• The study uses a qualitative narrative literature-review methodology, examining five major source documents through comparative thematic analysis. No questionnaire, laboratory experiment, or human-participant survey was conducted.
• Responsible implementation should follow a human-in-the-loop approach. Researchers should document data sources, test models on independent datasets, report uncertainty, experimentally validate important predictions, protect sensitive information, and clearly assign responsibility for AI-assisted decisions.
• AI systems should also be continuously monitored and reassessed, particularly when populations, datasets, instruments, or laboratory conditions change. These practices align with WHO principles concerning autonomy, safety, transparency, accountability, inclusiveness, and sustainability.

Conclusion

Artificial intelligence represents a transformative paradigm in biotechnology, offering key capabilities across drug discovery, genomics, diagnosis, personalized medicine, and biomanufacturing. However, AI cannot replace experimental evidence or biological expertise. Key challenges—including data quality, algorithmic bias, privacy risks, lack of explainability, and regulatory oversight—must be addressed before AI-generated insights are deployed in clinical or high-stakes settings. AI provides maximum value when used as a decision-support tool alongside laboratory validation and transparent scientific oversight.

References

[1] Bhushan, A., et al. (2025). Unlocking the potential: Multimodal AI in biotechnology. npj Digital Medicine. https://www.nature.com/articles/s41746-025-01992-6/ [2] Bassey, G. E., et al. (2025). Transformative role of artificial intelligence in drug discovery and development. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12406033/ [3] Zieli?ska, A., Fornalik, M., Szczepaniak, M., Gimla, M., Lema?ska, A., Cielecka-Piontek, J., & Souto, E. B. (2026). Artificial intelligence in drug research and development: a review of methods and applications in drug repurposing. Briefings in Bioinformatics, 27(3), bbag203. https://academic.oup.com/bib/article/27/3/bbag203/8689978 [4] World Health Organization. (2021). Ethics and governance of artificial intelligence for health: WHO guidance. https://iris.who.int/items/606b60cf-5e4d-409c-841b-0794c0978a19/ [5] Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., Bridgland, A., Meyer, C., Kohl, S. A. A., Ballard, A. J., Cowie, A., Romera-Paredes, B., Nikolov, S., Jain, R., Adler, J., ... Hassabis, D. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583–589. [6] Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., MacNair, C. R., French, S., Carfrae, L. A., Bloom-Ackermann, Z., Tran, V. M., Chiappino-Pepe, A., Badran, A. H., Andrews, I. W., Chory, E. J., Church, G. M., Brown, E. D., Jaakkola, T. S., Barzilay, R., & Collins, J. J. (2020). A deep learning approach to antibiotic discovery. Cell, 180(4), 688–702. [7] Bohr, A., & Memarzadeh, K. (2020). The rise of artificial intelligence in healthcare applications. Artificial Intelligence in Healthcare, 25–60. [8] Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: Present status and future prospects. Drug Discovery Today, 24(3), 773–780.*ingenuity, V., & Zhavoronkov, A. (2021). Artificial intelligence in drug discovery and development. Trends in Pharmacological Sciences, 42(5), 361–376. [9] Rives, A., Meier, J., Sercu, T., Goyal, S., Lin Z., Liu J., Guo D., Ott M., Zitnick C. L., Ma J., & Fergus R. (2021). Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences. Proceedings of the National Academy of Sciences, 118(15), e2016239118. [10] Schneider, P., Walters, W. P., Plowright, A. T., Sierzer, N., Southey, J., & Renner, S. (2020). Rethinking drug design in the artificial intelligence era. Nature Reviews Drug Discovery, 19(5), 353–364. [11] Yang, K. K., Wu, Z., & Arnold, F. H. (2019). Machine-learning-guided directed evolution for protein engineering. Nature Methods, 16(8), 687–694. [12] Alleman, E., & Zhang, Y. (2022). Deep learning and generative models in synthetic biology and metabolic engineering. Current Opinion in Biotechnology, 73, 245–252. [13] Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. Drug Discovery Today, 26(1), 80–93.

Copyright

Copyright © 2026 Mr. Danil Kumar Vaishnav, Dr. Mohammed Bakhtawar Ahmed. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.